OKLAHOMA CITY, Jan. 15, 2018 -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces and welcomes Edwin Miranda as Vice President of Quality. Edwin Miranda will be leading the full breadth of Cytovance’s Quality function.
“With over 33 years’ experience in the biopharmaceutical contract manufacturing industry, Edwin brings a depth of experience in quality assurance, encompassing solid & liquid oral dose, biologics and cosmetics,” said Dr. Jesse McCool, Sr. Vice President of Research & Development. “We are very fortunate to have such a well-seasoned and experienced executive join our team. Edwin’s knowledge and leadership skills will be tremendous assets to the Company.”
Prior to Cytovance, Edwin oversaw the Quality Assurance team in a successful FDA approval and launch of the New Drug Application (NDA) for Keppra®. He has served as Director of Quality or Vice President of Quality Assurance URL Mutual Pharmaceuticals, Inc., Legacy Pharmaceutical Packaging, and Piramal Critical Care, Inc. In these roles, he managed the quality systems, oversaw regulatory compliance functions, and developed a successful remediation plan to correct 483 observations, resulting in receipt of an Establishment Inspection Report (EIR) in good standing. Edwin, an army veteran, holds a B.S. in Biology & Chemistry from Angelo State University in San Angelo, TX.
“Edwin, comes to Cytovance in impeccable timing for Cytovance’s first PAI scheduled for February 2018,” commented Mike O’ Mara Sr. Vice President of Manufacturing Operations.” With a number of our clients getting ready to file BLA’s in 2018, Edwin’s expertise with FDA inspections will make him an invaluable addition to the Cytovance team.”
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Media Contact: Cheryl Tuck, [email protected]


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Explores AI Content Marketplace With Media Publishers
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Anta Sports Expands Global Footprint With Strategic Puma Stake
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



